StockData
Immix Biopharma, Inc. logo

Immix Biopharma, Inc. (IMMX) stock

IMMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$7.20−0.28 (-3.74%)

Close on Nov 17, 2026Market cap $515.08MP/E –Yield –

Immix Biopharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Immix Biopharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$38.50M. For fiscal 2025 it was -$23.93M. The highest annual figure on record is -$404.69K in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$23.93M–
FY2024Dec 31, 2024-$14.60M–
FY2023Dec 31, 2023-$11.37M–
FY2022Dec 31, 2022-$7.41M–
FY2021Dec 31, 2021-$1.59M–
FY2020Dec 31, 2020-$404.69K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$11.74M–
Q1 FY2026Mar 31, 2026-$9.83M–
Q4 FY2025Dec 31, 2025-$11.03M–
Q3 FY2025Sep 30, 2025-$5.91M–
Q2 FY2025Jun 30, 2025-$5.31M–
Q1 FY2025Mar 31, 2025-$1.69M–
Q4 FY2024Dec 31, 2024-$1.48M–
Q3 FY2024Sep 30, 2024-$4.04M–
Q2 FY2024Jun 30, 2024-$5.26M–
Q1 FY2024Mar 31, 2024-$3.83M–
Q4 FY2023Dec 31, 2023-$2.68M–
Q3 FY2023Sep 30, 2023-$3.09M–
Q2 FY2023Jun 30, 2023-$3.52M–
Q1 FY2023Mar 31, 2023-$2.09M–
Q4 FY2022Dec 31, 2022-$3.90M–
Q3 FY2022Sep 30, 2022-$1.46M–
Q2 FY2022Jun 30, 2022-$547.07K–
Q1 FY2022Mar 31, 2022-$1.49M–
Q4 FY2021Dec 31, 2021-$1.11M–
Q3 FY2021Sep 30, 2021-$50.76K–
Q2 FY2021Jun 30, 2021-$158.01K–
Q1 FY2021Mar 31, 2021-$266.45K–

More Immix Biopharma figures

See a number that looks wrong?